The Future of
Drug Discovery is Here.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Who We Are
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
What We Do
Duis irure dolor reprehenderit
in voluptate velit esse cillum
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
High-Throughput Screening
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Client Outcomes
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse.
News
Duis irure dolor reprehenderit
in voluptate velit esse cillum
Research results of a mouse model of chronic kidney disease (AXCC mice) generated in Axcelead DDP has been published in the American Journal of Pathology as a co-authored article.
A novel deep learning approach for analyzing glomerular basement membrane lesions in a mouse model of X-linked Alport...
A Co-authored Paper regarding Immunocompromised type 1 Diabetic Mini-pigs was Published in the Cell Transplantation
Xenogenic Engraftment of Human Induced Pluripotent Stem Cell–Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-pig...
Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals
September 10, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as...